XML 160 R144.htm IDEA: XBRL DOCUMENT v3.8.0.1
Parent Company Only Condensed Financial Statements - Statements of Financial Cash Flow (Details) - USD ($)
1 Months Ended 3 Months Ended 12 Months Ended
Jul. 06, 2017
Jul. 31, 2017
Dec. 31, 2017
Sep. 30, 2017
Jun. 30, 2017
Mar. 31, 2017
Dec. 31, 2016
Sep. 30, 2016
Jun. 30, 2016
Mar. 31, 2016
Dec. 31, 2017
Dec. 31, 2016
Dec. 31, 2015
CASH FLOWS FROM OPERATING ACTIVITIES                          
Net income (loss)     $ (766,000) $ 9,755,000 $ 6,146,000 $ 6,560,000 $ 63,915,000 $ 1,565,000 $ 2,601,000 $ (1,352,000) $ 21,695,000 $ 66,729,000 $ (14,974,000)
Adjustments to reconcile net income (loss) to net cash from operating activities:                          
Share-based compensation expense                     1,497,000 899,000 1,045,000
Exercise of share-based awards                       40,000  
Accretion of junior subordinated debentures discount                     721,000 876,000 944,000
CASH FLOWS FROM INVESTING ACTIVITIES                          
Net cash paid in acquisition of business                       (11,273,000)  
CASH FLOWS FROM FINANCING ACTIVITIES                          
Proceeds from revolving line of credit                       30,000,000  
Repayments of revolving line of credit   $ (16,200,000)                 (20,650,000) (9,350,000)  
Dividends paid on preferred stock                     (11,277,000)    
Cash paid in lieu of fractional shares                     (2,000)    
Proceeds from issuance of common stock, net $ 82,700,000                   76,829,000 49,592,000  
Proceeds from issuance of preferred stock                     1,050,000 9,388,000  
Repurchase of preferred stock                     (15,003,000)    
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS                     11,816,000 1,649,000 (111,769,000)
CASH AND CASH EQUIVALENTS, beginning of period           46,533,000       44,884,000 46,533,000 44,884,000 156,653,000
CASH AND CASH EQUIVALENTS, end of period     58,349,000       46,533,000       58,349,000 46,533,000 44,884,000
Company                          
CASH FLOWS FROM OPERATING ACTIVITIES                          
Net income (loss)                     21,695,000 66,729,000 (14,974,000)
Adjustments to reconcile net income (loss) to net cash from operating activities:                          
Equity in undistributed income (loss) of subsidiary                     (22,306,000) (69,717,000) 12,359,000
Share-based compensation expense                     1,497,000 899,000 1,045,000
Exercise of share-based awards                       40,000  
Accretion of junior subordinated debentures discount                     721,000 876,000 944,000
Changes in other assets and other liabilities                     (2,893,000) 16,000 (5,546,000)
Net cash used in operating activities                     (1,286,000) (1,157,000) (6,172,000)
CASH FLOWS FROM INVESTING ACTIVITIES                          
Investments in and advances from subsidiary                       (32,019,000)  
Net cash paid in acquisition of business                       (36,586,000)  
Net cash used in investing activities                       (68,605,000)  
CASH FLOWS FROM FINANCING ACTIVITIES                          
Proceeds from revolving line of credit                       30,000,000  
Repayments of revolving line of credit                     (20,650,000) (9,350,000)  
Dividends paid on preferred stock                     (11,277,000)    
Cash paid in lieu of fractional shares                     (2,000)    
Proceeds from issuance of common stock, net                     76,829,000 49,592,000  
Proceeds from issuance of preferred stock                     1,050,000 9,388,000  
Repurchase of preferred stock                     (15,003,000)    
Net cash provided by financing activities                     30,947,000 79,630,000  
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS                     29,661,000 9,868,000 (6,172,000)
CASH AND CASH EQUIVALENTS, beginning of period           $ 9,965,000       $ 97,000 9,965,000 97,000 6,269,000
CASH AND CASH EQUIVALENTS, end of period     $ 39,626,000       $ 9,965,000       $ 39,626,000 $ 9,965,000 $ 97,000